About Allterum
Allterum is a company based in Houston (United States) founded in 2018. Allterum has raised $65.8 million across 3 funding rounds from investors including Orbimed, Arjun Goyal and Nextech Invest. Allterum offers products and services including CD127 Monoclonal Antibody. Allterum operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
- Headquarter Houston, United States
- SectorsHealthcare
- Email••••••••
- Website allterum.com
- Legal Name Allterum Therapeutics, Inc.
- Total Equity Funding$65.8M (USD)
in 3 rounds
- Latest Funding Round$64M (USD), Series A
Jan 2022
- InvestorsOrbimed
& 5 more
Products & Services of Allterum
Allterum offers a comprehensive portfolio of products and services, including CD127 Monoclonal Antibody.
Targets CD127 for treating hematologic malignancies and solid tumors.
Funding Insights of Allterum
Allterum has successfully raised a total of $65.8M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $64 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65.8M
- Total Rounds 3
- Last Round Series A — $64M
- First Round $2.9M
(Apr 2020)
- Investors Count 6
All 3 funding rounds of Allterum with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $64M | Series A | – | Orbimed, Nextech Invest | |
| Dec 2020 | $1.8M | Seed | – | Fannin Innovation Studio | – |
| Apr 2020 | $2.9M | Grant | – | – |
6 investors in total: 5 institutional and 1 angel.
Investors in Allterum
Allterum has secured backing from 6 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Orbimed, Arjun Goyal and Nextech Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
PE firm investing in the US | – | nextechinvest.com | Zurich, Switzerland | |
Biotech startups are funded by this venture capital firm. | – | boxercap.com | San Diego, United States | |
Early-stage biomedical assets are developed by Fannin for vital needs. | 2014 | fannininnovation.com | Houston, United States | |
- | – | cprit.texas.gov | - | |
AG Arjun Goyal | Co-founder of Stanza Living, active angel investor in Indian startups | – | unknown_a22b0743be7841019 | - |
Investor details for Allterum
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Allterum
9 people are tracked at Allterum (7 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Atul Varadhachary | CEO | President | Leadership |
Philip Breitfeld | Chief Medical Officer | Leadership |
Mark Worscheh | CFO | Leadership |
Michael Heffernan | Director, Operations | Leadership |
Ross Clary | Director, Business Development | Leadership |
Jack Schaumberg | Director, Clinical Operations | Leadership |
Leo Linbeck | Director, Accounting & Finance | Leadership |
Scott Durum | Collaborator | Team |
Susan Rheingold | Collaborator | Team |
Complete people profiles for Allterum
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Allterum
3 dated milestones of Allterum across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Allterum is founded.
- Funding First funding round of $2.9M.
- Funding Latest funding round, Series A, of $64.0M.
Competitors of Allterum
Allterum operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| lyell.com | 2018 | San Francisco, United States | $493M | 224 | CAR-T and TIL immunotherapies for solid tumors are developed. | |
| autolus.com | 2015 | London, United Kingdom | $181.37M | 51 | Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | |
| cabalettabio.com | 2017 | Radnor, United States | $88.26M | 60 | Developer of CAAR T cells for B cell-mediated autoimmune diseases | |
| immatics.com | 2000 | Tubingen, Germany | $236.4M | 198 | T-cell-based immunotherapies for cancer treatment are developed. | |
| cargo-tx.com | 2021 | San Mateo, United States | $200M | 42 | Cell-based therapeutics for cancer treatment are developed. | |
| achillestx.com | 2016 | London, United Kingdom | $241.98M | 118 | T-cell therapies targeting tumor neo-antigens for cancer are developed. |
Detailed competitors of Allterum
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Allterum
The website of Allterum (allterum.com) receives about 1.1K visits a month.
- Monthly visits1.1K
Latest news on Allterum
Complete news archive for Allterum
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Allterum
10 companies that operate in the same segment as Allterum (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Allterum
Allterum was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Allterum is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Allterum is a funded company, having raised a total of $65.8M across 3 funding rounds to date. The company's 1st funding round was a Grant of $2.9M, raised on Apr 2020.
Allterum was founded in 2018 in Houston, United States, within the biotechnology sector. Focus is placed on developing drugs for leukemia treatment, particularly monoclonal antibody therapies targeting pediatric acute lymphoblastic leukemia. Additional efforts involve identifying T-cell origin cancers to enable precise patient treatment. Operations center on oncology research and therapeutic innovation for hematologic malignancies.
Allterum's top competitors include Juno Therapeutics, Lyell Immunopharma and Immatics.
Allterum offers CD127 Monoclonal Antibody.
Allterum has 6 investors. Key investors include Orbimed, Arjun Goyal, Nextech Invest, Boxer Capital, and Fannin.
Allterum operates through Allterum Therapeutics, Inc..